What Caused The Madrigal Pharmaceuticals (MDGL) Stock To Rise In Pre-Market Trades?
The clinical-stage biopharmaceutical firm Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) has increased 211.13% to $198.50 in pre-market trading on the most recent Monday after announcing topline clinical trial results. What outcomes has MDGL announced? Resmetirom, a liver-directed specific thyroid hormone receptor agonist, was tested in the key Phase 3 MAESTRO-NASH biopsy research study by Madrigal Pharmaceuticals […]